ADMA Biologics Inc. [ADMA] stock for 42,851 USD was bought by Grossman Adam S


Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. ADMA Biologics Inc. shares valued at $42,851 were purchased by Grossman Adam S on Dec 09. At $2.86 per share, Grossman Adam S acquired 14,983 shares. The insider’s holdings grew to 2,203,708 shares worth approximately $7.82 million following the completion of this transaction.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Also, Grossman Adam S purchased 14,982 shares, netting a total of over 42,849 in proceeds. Following the buying of shares at $2.86 each, the insider now holds 1,143,426 shares.

Before that, LENZ BRIAN had added 6,993 shares to its account. In a trade valued at $20,000, the EVP, CFO bought ADMA Biologics Inc. shares for $2.86 each. Upon closing the transaction, the insider’s holdings increased to 6,993 shares, worth approximately $3.67 million.

As published in their initiating research note from Mizuho on October 13, 2022, ADMA Biologics Inc. [ADMA] has been a Buy and the price target has been revised to $5. This represents a 29.0% premium over Wednesday’s closing price. Analysts at Raymond James upgraded the stock from ‘”an Outperform”‘ to ‘”a Strong buy”‘ outlook in a report released in mid November. As of November 09, 2021, Cantor Fitzgerald has initiated its “an Overweight” rating for ADMA. Earlier on June 04, 2019, Jefferies initiated its rating. Their recommendation was “a Buy” for ADMA stock.

Analyzing ADMA Stock Performance

The stock’s lowest price that day was $3.54, but it reached a high of $3.6699 in the same session. During the last five days, there has been a surge of approximately 1.14%. Over the course of the year, ADMA Biologics Inc. shares have dropped approximately -8.51%. Shares of the company reached a 52-week high of $3.98 on 01/03/23 and a 52-week low of $3.26 on 01/20/23. A 50-day SMA is recorded $3.60, while a 200-day SMA reached $2.79. Nevertheless, trading volume fell to 1.82 million shares from 1.63 million shares the previous day.

Support And Resistance Levels for ADMA Biologics Inc. (ADMA)

According to the 24-hour chart, there is a support level at 3.50, which, if violated, would cause prices to drop to 3.46. In the upper region, resistance lies at 3.63. The next price resistance is at 3.72. RSI (Relative Strength Index) is 48.97 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.02, which suggests the price will decrease in the coming days. Percent R is at 67.03%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is ADMA Biologics Inc. subject to short interest?

Stocks of ADMA Biologics Inc. saw a sharp rise in short interest on Jan 30, 2023 jumping by 70000.0 shares to 12.79 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 12.72 million shares. A jump of 0.55% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.91 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.91.

Which companies own the most shares of ADMA Biologics Inc. (ADMA)?

According to BlackRock Fund Advisors filings, the company currently owns 13,488,055 shares, which is about 6.11% of the total ADMA shares outstanding. The investor’s shares have appreciated by 2,118,015 from its previous 13-F filing of 11370040.0 shares. With the completion of the buy transaction, Perceptive Advisors LLC’s stake is now worth $43,911,941. SSgA Funds Management, Inc. acquire a 16.81% interest valued at $40.62 million while The Vanguard Group, Inc. purchased a 1,449,336 stake. A total of 2,664,613 shares of ADMA Biologics Inc. were bought by D. E. Shaw & Co. LP during the quarter, and 1,940,000 were bought by Stonepine Capital Management LLC. In its current portfolio, Magnetar Financial LLC holds 6,187,316 shares valued at $22.83 million.

In terms of ADMA Biologics Inc. share price expectations, FactSet research, analysts set an average price target of $5.13 in the next 12 months, up nearly 40.85% from the previous closing price of $3.55. Analysts anticipate ADMA Biologics Inc. stock to reach $6.00 by 2023, with the lowest price target being $4.50. In spite of this, 4 analysts ranked ADMA Biologics Inc. stock as a Buy at the end of 2023. On April 15, 2019, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $13.


Please enter your comment!
Please enter your name here